Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search



Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search


15 results
12:00 AM, Jan 18, 2016  |  BioCentury | Strategy

Shire's serial story

2014. Shire has no cancer therapies in its pipeline. It does market one hematology drug: Xagrid
anagrelide for essential thrombocythemia, a rare blood disease associated with the increased production of blood platelets …
12:00 AM, Aug 10, 2015  |  BioCentury | Strategy

Shire's M&A stepping stone

a single cancer product on the market: Baxalta's recently acquired leukemia drug Oncaspar and Shire's Xagrid
anagrelide, which is marketed for essential thrombocytopenia. Both generate about $100 million in annual sales. Enyedy …
model." Of Baxalta's four late-stage cancer programs, three are for hematological malignancies. Enyedy added that Xagrid
12:00 AM, May 27, 2013  |  BioCentury | Strategy

Royalty pain or gain

disorders in Central Europe, the Commonwealth of Independent States (CIS) and the Middle East. AOP's anagrelide
12:00 AM, May 20, 2013  |  BioCentury | Strategy

R&D rewind

portfolio includes ADHD drug Adderall XR dextroamphetamine/amphetamine, hyperphosphatemia drug Fosrenol lanthanum carbonate and thrombocytopenia drug Xagrid
anagrelide. Companies and Institutions Mentioned Bayer AG (Xetra:BAYN), Leverkusen, Germany Bausch & Lomb Inc. , Rochester …
12:00 AM, Apr 02, 2012  |  BioCentury | Strategy

Shire's iron backbone

unit in areas that are specialty focused," he said. The company markets the hematology product Xagrid
anagrelide, a small molecule to reduce elevated platelet counts in at-risk essential thrombocythemia patients who are …
intolerant of or do not respond to hydroxyurea therapy. Xagrid had 2011 sales of $90.6 million …
12:00 AM, Aug 09, 2010  |  BioCentury | Strategy

Shire Early and Late

Intrathecal formulation of Elaprase idursulfase MPS-II (Hunter syndrome) with significant CNS symptoms Ph I/II SPD535 Anagrelide
12:00 AM, Jun 25, 2007  |  BioCentury | Strategy

Shire product sales

ADHD $863.6 Pentasa [Ferring] Ulcerative colitis (UC) $137.8 Replagal Fabry's disease $117.7 Carbatrol Epilepsy $68.3 Agrylin/Xagrid
12:00 AM, Feb 26, 2007  |  BioCentury | Strategy

Shire at the river’s edge

the 1999 purchase of Roberts Pharmaceutical Corp. for $1 billion in stock. The deal brought Agrylin
anagrelide to treat elevated platelets, Pentasa mesalamine to treat ulcerative colitis (UC) and ProAmatine midodrine to …
12:00 AM, Apr 25, 2005  |  BioCentury | Strategy

Stronger Context: The commercial imperative

sales: $607 million) through the takeover of Richwood Pharmaceutical Co. Inc. in 1997, and of Agrylin
anagrelide for thrombocythemia ($152.5 million) and Pentasa for ulcerative colitis ($115 million), obtained in the acquisition …
12:00 AM, Apr 25, 2005  |  BioCentury | Strategy

Shire-Transkaryotic pipeline

Indication Status (Milestones) Company Adderall & Adderall XR Attention deficit hyperactivity disorder (ADHD) Mkt SHP Agrylin
SHP/Ferring Proamatine/Amatine Symptomatic orthostatic hypotension Mkt SHP/Nycomed Reminyl Alzheimer's disease Mkt SHP/J&J (Janssen)/ Synaptech (A) Xagrid